Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation - Concepedia

Concepedia

Publication | Open Access

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation

DOI Full Paper Access

94

Citations

29

References

2014

Year

Paul Dorian, Thitima Kongnakorn, Hemant Phatak, Dale Rublee, Andreas Kuznik, Tereza Lanitis, Liu Lz, U Iloeje, Luis Hernández, Gregory Y.H. Lip

European Heart Journal

Abstract

Based on randomized trial data, apixaban is a cost-effective alternative to warfarin and aspirin, in VKA suitable and VKA unsuitable patients with AF, respectively.

References

	Year	Citations

Page 1